The gross proceeds of the credit agreement at closing are
Armata also announced today a leadership transition whereby Dr.
About
Armata is a clinical stage biotechnology company focused on the development of pathogen specific bacteriophage therapeutics for the treatment of antibiotic resistant and difficult to treat bacterial infections using its proprietary bacteriophage based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in house phage specific GMP manufacturing.
Contact:
Email: ir@armatapharma.com
Tel: 310 665 2928
(C) 2023 Electronic News Publishing, source